½ÃÀ庸°í¼­
»óǰÄÚµå
1790266

³²¼º ¿ä½Ç±Ý ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿ä½Ç±Ý À¯Çüº°, »ç¿ë¹ýº°, À¯Åë ä³Îº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2033³â)

Male Urinary Incontinence Market Size, Share & Trends Analysis Report By Product, By Incontinence Type (Stress Urinary Incontinence, Urge Urinary Incontinence), By Usage, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2025 - 2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

³²¼º ¿ä½Ç±Ý ½ÃÀå °³¿ä

³²¼º ¿ä½Ç±Ý ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 71¾ï ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2033³â¿¡´Â 119¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç 2025-2033 ³â¿¡´Â 5.97%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº Àα¸ÀÇ °í·ÉÈ­, Àü¸³¼± °ü·Ã ¼ö¼ú Áõ°¡, ¿ä½Ç±Ý °ü¸®¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.

³²¼º¿ë ½½¸µ, Àΰø¿äµµ°ý¾à±Ù, ÀÚ±âÀڱر⠵î ÀÇ·á±â¼úÀÇ ¹ßÀüÀº ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϰí äÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °¢ Áö¿ª¿¡¼­ ÀÓ»ó½ÃÇèÀÇ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á Á¢±Ù ¹æ½ÄÀÇ Çõ½ÅÀÌ ´õ¿í °­Á¶µÇ°í Ä¡·á ÆÄÀÌÇÁ¶óÀÎÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ij³ª´Ù ¾ÏÇùȸ¿¡ µû¸£¸é, 2024³â¿¡µµ Àü¸³¼±¾ÏÀº ij³ª´Ù ³²¼ºÀÇ °Ç°­»ó Áß¿äÇÑ °ü½É»çÀ̸ç, ¾à 2¸¸ 7,900¸íÀÌ »õ·Î Áø´ÜÀ» ¹Þ¾Æ ³²¼º¿¡¼­ »õ·Î Áø´ÜµÇ´Â ¾ÏÀÇ 22%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Àü¸³¼±¾ÏÀº ÁÖ·Î Ä¡·á ÈÄ ¹ß»ýÇÏ´Â ¹è´¢ ÇÕº´ÁõÀÇ ³ôÀº ¹ß»ý·ü·Î ÀÎÇØ ³²¼º ¿ä½Ç±Ý »ê¾÷ÀÇ ¼ºÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀÌ µÇ¾ú½À´Ï´Ù. Àü¸³¼±¾Ï Ä¡·á, ƯÈ÷ ±ÙÄ¡Àû Àü¸³¼± ÀýÁ¦¼ú(Àü¸³¼±ÀÇ ¿Ü°úÀû ÀýÁ¦), ¹æ»ç¼± Ä¡·á, È£¸£¸ó Ä¡·á´Â °ñ¹ÝÀú±ÙÀ°, °ý¾à±Ù, ¹æ±¤ ±â´ÉÀÇ ½É°¢ÇÑ ¼Õ»ó°ú ¾àÈ­¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú ½ºÆ®·¹½º¼º ¿ä½Ç±Ý, Àý¹Ú¼º ¿ä½Ç±Ý ¶Ç´Â È¥ÇÕÇü ¿ä½Ç±ÝÀÌ ¹ß»ýÇÕ´Ï´Ù. Àü¸³¼± ÀýÁ¦¼ú ÈÄ ¿ä½Ç±ÝÀº °¡Àå ÈçÇÑ ÇÕº´Áõ Áß Çϳª·Î, ¼ö¼ú ÈÄ ¼ö°³¿ù¿¡¼­ ¼ö³â »çÀÌ¿¡ »ó´ç¼öÀÇ ³²¼ºÀÌ °Þ°Ô µË´Ï´Ù. ¸¶Âù°¡Áö·Î ¹æ»ç¼± Ä¡·á´Â ¹æ±¤ ÀÚ±Ø, Àú·ù ¿ë·® °¨¼Ò, ºñÀÚ¹ßÀû ¼Òº¯ ´©ÃâÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü¸³¼±¾Ï Ä¡·á ÈÄ »ýÁ¸À²ÀÌ Çâ»óµÇ°í, Àü¸³¼±¾Ï Ä¡·á ÈÄ ´õ ¿À·¡ »ç´Â ³²¼ºÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿ä½Ç±Ý À¯º´·üµµ Áõ°¡ÇÏ¿© È¿°úÀûÀÎ °ü¸® ¿É¼Ç¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ³²¼º ¿ä½Ç±Ý ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦ ºÐ¼®
    • ½ÃÀå ±âȸ ºÐ¼®
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå ºÐ¼® Åø
    • »ê¾÷ ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ³²¼º ¿ä½Ç±Ý ½ÃÀå : Á¦Ç°º°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ³²¼º ¿ä½Ç±Ý ½ÃÀå : Á¦Ç° ´ë½Ãº¸µå
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø¡¤µ¿Ç⠺м®(Á¦Ç°º°, 2021-2033³â)
    • ºñÈí¼ö¼º
    • Èí¼ö¼º

Á¦5Àå ³²¼º ¿ä½Ç±Ý ½ÃÀå : ¿ä½Ç±Ý À¯Çüº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ³²¼º ¿ä½Ç±Ý ½ÃÀå : ¿ä½Ç±Ý À¯Çü ´ë½Ãº¸µå
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå : ¿ä½Ç±Ý À¯Çü º¯µ¿ ºÐ¼®
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø¡¤µ¿Ç⠺м®(¿ä½Ç±Ý À¯Çüº°, 2021-2033³â)
    • º¹¾Ð¼º ¿ä½Ç±Ý
    • ÀÓ¹Ú¼º ¿ä½Ç±Ý
    • ÀÏ·ù¼º ¿ä½Ç±Ý
    • ±â´É¼º ¿ä½Ç±Ý
    • È¥ÇÕ¼º ¿ä½Ç±Ý

Á¦6Àå ³²¼º ¿ä½Ç±Ý ½ÃÀå : »ç¿ë¹ýº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ³²¼º ¿ä½Ç±Ý ½ÃÀå : »ç¿ë¹ý ´ë½Ãº¸µå
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå : »ç¿ë¹ýº¯µ¿ ºÐ¼®
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø¡¤µ¿Ç⠺м®(»ç¿ë¹ýº°, 2021-2033³â)
    • ÀçÀÌ¿ë °¡´É
    • ÀÏȸ¿ë

Á¦7Àå ³²¼º ¿ä½Ç±Ý ½ÃÀå : À¯Åë ä³Îº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ³²¼º ¿ä½Ç±Ý ½ÃÀå : À¯Åë ä³Î ´ë½Ãº¸µå
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå : À¯Åë ä³Î º¯µ¿ ºÐ¼®
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø¡¤µ¿Ç⠺м®(À¯Åë ä³Îº°, 2021-2033³â)
    • ¿ÀÇÁ¶óÀÎ ½ºÅä¾î
    • ¿Â¶óÀΠä³Î

Á¦8Àå ³²¼º ¿ä½Ç±Ý ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ³²¼º ¿ä½Ç±Ý ½ÃÀå : ÃÖÁ¾ ¿ëµµ ´ë½Ãº¸µå
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ³²¼º ¿ä½Ç±Ý ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø¡¤µ¿Ç⠺м®(ÃÖÁ¾ ¿ëµµº°, 2021-2033³â)
    • º´¿ø ¹× Ŭ¸®´Ð
    • ÀçÅÃÄ¡·á
    • ±âŸ

Á¦9Àå ³²¼º ¿ä½Ç±Ý ½ÃÀå : Á¦Ç°, ¿ä½Ç±Ý À¯Çü, »ç¿ë¹ý, À¯Åë ä³Î, ÃÖÁ¾ ¿ëµµ, Áö¿ª¿¡ ÀÇÇÑ Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¼¼°èÀÇ ³²¼º ¿ä½Ç±Ý ½ÃÀå : Áö¿ªº° ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®, 2021-2033³â
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦10Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷/°æÀï ºÐ·ù
    • Çõ½Å±â¾÷
  • º¥´õ ±¸µµ
    • ÁÖ¿ä À¯Åë¾÷ü¿Í ä³Î ÆÄÆ®³Ê ¸®½ºÆ®
    • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
    • Essity
    • Boston Scientific Corporation
    • Kimberly-Clark Worldwide Inc.
    • Attends Healthcare Products, Inc.(Domtar Corporation)
    • ABENA
    • Ontex Healthcare
    • PAUL HARTMANN AG
    • Teleflex Incorporated
    • First Quality
    • Coloplast Corp.
    • Medline
    • BD
    • Hollister Incorporated
    • Cardinal Health
LSH 25.08.25

Male Urinary Incontinence Market Summary

The global male urinary incontinence market size was estimated at USD 7.10 billion in 2024 and is projected to reach USD 11.92 billion by 2033, growing at a CAGR of 5.97% from 2025 to 2033. This growth is attributed to the aging population, rising incidence of prostate-related surgeries, and increasing awareness about incontinence management.

Advancements in medical technology, including male slings, artificial urinary sphincters, and magnetic stimulation devices, are improving patient outcomes and driving adoption. The growing number of clinical trials across regions further underscores innovation in treatment approaches, expanding the therapeutic pipeline. According to the Canadian Cancer Society, in 2024, prostate cancer remains a significant health concern among Canadian men, with approximately 27,900 new diagnoses, accounting for 22% of all newly diagnosed cancer cases in men.

Prostate cancer is a major driver of the male urinary incontinence industry's growth, mainly due to the high incidence of urinary complications that arise following its treatment. Prostate cancer treatments, particularly radical prostatectomy (surgical removal of the prostate gland), radiotherapy, and hormone therapy, can lead to significant damage or weakening of the pelvic floor muscles, sphincter mechanism, and bladder function. This results in stress urinary incontinence, urge incontinence, or mixed forms of incontinence. Post-prostatectomy incontinence is one of the most common complications, affecting a substantial proportion of men in the months and even years following surgery. Similarly, radiation therapy can cause bladder irritation, reduced storage capacity, and involuntary leakage. As survival rates improve and more men live longer after prostate cancer treatment, the prevalence of urinary incontinence also rises, creating sustained demand for effective management options.

Global Male Urinary Incontinence Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global male urinary incontinence market report based on product, incontinence type, usage, distribution channel, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Non-Absorbents
    • Urinary Catheters
    • Foley Catheters
    • External Catheters
    • Drainage Bags
    • External Compression Devices/Penile Clamps
    • Artificial Urinary Sphincter
    • Others
  • Absorbents
    • Underwear & Briefs
    • Drip Collectors & Bed Protectors
    • Pads & Guards
  • Incontinence Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Stress Urinary Incontinence
  • Urge Urinary Incontinence
  • Overflow Incontinence
  • Functional Urinary Incontinence
  • Mixed Urinary Incontinence
  • Usage Outlook (Revenue, USD Million, 2021 - 2033)
  • Reusable
  • Disposable
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Offline Stores
  • Online Channels
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Homecare
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Norway
    • Denmark
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Incontinence type
    • 1.1.3. Usage
    • 1.1.4. Distribution channel
    • 1.1.5. End Use
    • 1.1.6. Regional scope
    • 1.1.7. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity price analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Incontinence type outlook
    • 2.2.3. Usage outlook
    • 2.2.4. Distribution channel outlook
    • 2.2.5. End use outlook
    • 2.2.6. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Male Urinary Incontinence Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of urinary incontinence
      • 3.2.1.2. Growing geriatric population
      • 3.2.1.3. Rapid technological advancements
      • 3.2.1.4. Rise in demand for minimally invasive procedures
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Growing concerns regarding catheter associated urinary tract infection
      • 3.2.2.2. Availability of alternatives
    • 3.2.3. Market Challenge Analysis
      • 3.2.3.1. Social stigma and psychological barriers
    • 3.2.4. Market Opportunity Analysis
      • 3.2.4.1. Expansion in home healthcare
      • 3.2.4.2. Product innovation & customization
  • 3.3. Male Urinary Incontinence Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Male Urinary Incontinence Market: Product Estimates & Trend Analysis

  • 4.1. Male Urinary Incontinence Market: Product Dashboard
  • 4.2. Male Urinary Incontinence Market: Product Movement Analysis
  • 4.3. Male Urinary Incontinence Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
    • 4.3.1. Non-Absorbents
      • 4.3.1.1. Non-absorbents market estimates and forecast 2021 to 2033 (USD Million)
      • 4.3.1.2. Urinary catheters
        • 4.3.1.2.1. Urinary catheters market estimates and forecast 2021 to 2033 (USD Million)
        • 4.3.1.2.2. Foley catheters
          • 4.3.1.2.2.1. Foley catheters market estimates and forecast 2021 to 2033 (USD Million)
        • 4.3.1.2.3. External catheters
          • 4.3.1.2.3.1. External catheters market estimates and forecast 2021 to 2033 (USD Million)
      • 4.3.1.3. Drainage bags
        • 4.3.1.3.1. Drainage bags market estimates and forecast 2021 to 2033 (USD Million)
      • 4.3.1.4. External compression devices/penile clamps
        • 4.3.1.4.1. External compression devices/penile clamps market estimates and forecast 2021 to 2033 (USD Million)
      • 4.3.1.5. Artificial urinary sphincter
        • 4.3.1.5.1. Artificial urinary sphincter market estimates and forecast 2021 to 2033 (USD Million)
      • 4.3.1.6. Others
        • 4.3.1.6.1. Others market estimates and forecast 2021 to 2033 (USD Million)
    • 4.3.2. Absorbents
      • 4.3.2.1. Absorbents market estimates and forecast 2021 to 2033s (USD Million)
      • 4.3.2.2. Underwear & Briefs
        • 4.3.2.2.1. Underwear & briefs market estimates and forecast 2021 to 2033 (USD Million)
      • 4.3.2.3. Drip Collectors & Bed Protectors
        • 4.3.2.3.1. Drip collectors & bed protectors market estimates and forecast 2021 to 2033 (USD Million)
      • 4.3.2.4. Pads & Guards
        • 4.3.2.4.1. Pads & guards market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Male Urinary Incontinence Market: Incontinence Type Estimates & Trend Analysis

  • 5.1. Male Urinary Incontinence Market: Incontinence Type Dashboard
  • 5.2. Male Urinary Incontinence Market: Incontinence Type Movement Analysis
  • 5.3. Male Urinary Incontinence Market Size & Forecasts and Trend Analysis, by Incontinence Type, 2021 to 2033 (USD Million)
    • 5.3.1. Stress Urinary Incontinence
      • 5.3.1.1. Stress urinary incontinence market estimates and forecast 2021 to 2033 (USD Million)
    • 5.3.2. Urge Urinary Incontinence
      • 5.3.2.1. Urge urinary incontinence market estimates and forecast 2021 to 2033 (USD Million)
    • 5.3.3. Overflow Incontinence
      • 5.3.3.1. Overflow incontinence market estimates and forecast 2021 to 2033 (USD Million)
    • 5.3.4. Functional Urinary Incontinence
      • 5.3.4.1. Functional urinary incontinence market estimates and forecast 2021 to 2033 (USD Million
    • 5.3.5. Mixed Urinary Incontinence
      • 5.3.5.1. Mixed urinary incontinence market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Male Urinary Incontinence Market: Usage Estimates & Trend Analysis

  • 6.1. Male Urinary Incontinence Market: Usage Dashboard
  • 6.2. Male Urinary Incontinence Market: Usage Movement Analysis
  • 6.3. Male Urinary Incontinence Market Size & Forecasts and Trend Analysis, by Usage, 2021 to 2033 (USD Million)
    • 6.3.1. Reusable
      • 6.3.1.1. Reusable market estimates and forecast 2021 to 2033 (USD Million)
    • 6.3.2. Disposable
      • 6.3.2.1. Disposable market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Male Urinary Incontinence Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Male Urinary Incontinence Market: Distribution Channel Dashboard
  • 7.2. Male Urinary Incontinence Market: Distribution Channel Movement Analysis
  • 7.3. Male Urinary Incontinence Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
    • 7.3.1. Offline Stores
      • 7.3.1.1. Offline stores market estimates and forecast 2021 to 2033 (USD Million)
    • 7.3.2. Online Channels
      • 7.3.2.1. Online channels market estimates and forecast 2021 to 2033 (USD Million)

Chapter 8. Male Urinary Incontinence Market: End Use Estimates & Trend Analysis

  • 8.1. Male Urinary Incontinence Market: End Use Dashboard
  • 8.2. Male Urinary Incontinence Market: End Use Movement Analysis
  • 8.3. Male Urinary Incontinence Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
    • 8.3.1. Hospitals & Clinics
      • 8.3.1.1. Hospitals & clinics market estimates and forecast 2021 to 2033 (USD Million)
    • 8.3.2. Homecare
      • 8.3.2.1. Homecare market estimates and forecast 2021 to 2033 (USD Million)
    • 8.3.3. Others
      • 8.3.3.1. Others market estimates and forecast 2021 to 2033 (USD Million)

Chapter 9. Male Urinary Incontinence Market: Regional Estimates & Trend Analysis by Product, Incontinence Type, Usage, Distribution Channel, End Use, and Region

  • 9.1. Global Male Urinary Incontinence Market: Regional Dashboard
  • 9.2. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 9.3. North America
    • 9.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 9.3.2. U.S.
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework/ reimbursement structure
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. U.S. market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.3.3. Canada
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework/ reimbursement structure
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Canada market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.3.4. Mexico
      • 9.3.4.1. Key country dynamics
      • 9.3.4.2. Regulatory framework/ reimbursement structure
      • 9.3.4.3. Competitive scenario
      • 9.3.4.4. Mexico market estimates and forecast, 2021 - 2033 (USD Million)
  • 9.4. Europe
    • 9.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 9.4.2. UK
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework/ reimbursement structure
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. UK market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.4.3. Germany
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework/ reimbursement structure
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. Germany market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.4.4. France
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework/ reimbursement structure
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. France market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.4.5. Italy
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework/ reimbursement structure
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Italy market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.4.6. Spain
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework/ reimbursement structure
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. Spain market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.4.7. Sweden
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework/ reimbursement structure
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Sweden market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.4.8. Norway
      • 9.4.8.1. Key country dynamics
      • 9.4.8.2. Regulatory framework/ reimbursement structure
      • 9.4.8.3. Competitive scenario
      • 9.4.8.4. Norway market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.4.9. Denmark
      • 9.4.9.1. Key country dynamics
      • 9.4.9.2. Regulatory framework/ reimbursement structure
      • 9.4.9.3. Competitive scenario
      • 9.4.9.4. Denmark market estimates and forecast, 2021 - 2033 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 9.5.2. China
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework/ reimbursement structure
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. China market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.5.3. Japan
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework/ reimbursement structure
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. Japan market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.5.4. India
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework/ reimbursement structure
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. India market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.5.5. Australia
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. Regulatory framework/ reimbursement structure
      • 9.5.5.3. Competitive scenario
      • 9.5.5.4. Australia market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Regulatory framework/ reimbursement structure
      • 9.5.6.3. Competitive scenario
      • 9.5.6.4. Thailand market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.5.7. South Korea
      • 9.5.7.1. Key country dynamics
      • 9.5.7.2. Regulatory framework/ reimbursement structure
      • 9.5.7.3. Competitive scenario
      • 9.5.7.4. South Korea market estimates and forecast, 2021 - 2033 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 9.6.2. Brazil
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework/ reimbursement structure
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. Brazil market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.6.3. Argentina
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Regulatory framework/ reimbursement structure
      • 9.6.3.3. Competitive scenario
      • 9.6.3.4. Argentina market estimates and forecast, 2021 - 2033 (USD Million)
  • 9.7. MEA
    • 9.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 9.7.2. Saudi Arabia
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework/ reimbursement structure
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.7.3. South Africa
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework/ reimbursement structure
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. South Africa market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.7.4. UAE
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework/ reimbursement structure
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. UAE market estimates and forecast, 2021 - 2033 (USD Million)
    • 9.7.5. Kuwait
      • 9.7.5.1. Key country dynamics
      • 9.7.5.2. Regulatory framework/ reimbursement structure
      • 9.7.5.3. Competitive scenario
      • 9.7.5.4. Kuwait market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
    • 10.2.1. Innovators
  • 10.3. Vendor Landscape
    • 10.3.1. List of key distributors and channel partners
    • 10.3.2. Key customers
    • 10.3.3. Key company market share analysis, 2024
    • 10.3.4. Essity
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Usage benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Boston Scientific Corporation
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Usage benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Kimberly-Clark Worldwide Inc.
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Usage benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. Attends Healthcare Products, Inc. (Domtar Corporation)
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Usage benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. ABENA
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Usage benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Ontex Healthcare
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Usage benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. PAUL HARTMANN AG
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Usage benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. Teleflex Incorporated
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Usage benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. First Quality
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Usage benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. Coloplast Corp.
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Usage benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Medline
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Usage benchmarking
      • 10.3.14.4. Strategic initiatives
    • 10.3.15. BD
      • 10.3.15.1. Company overview
      • 10.3.15.2. Financial performance
      • 10.3.15.3. Usage benchmarking
      • 10.3.15.4. Strategic initiatives
    • 10.3.16. Hollister Incorporated
      • 10.3.16.1. Company overview
      • 10.3.16.2. Financial performance
      • 10.3.16.3. Usage benchmarking
      • 10.3.16.4. Strategic initiatives
    • 10.3.17. Cardinal Health
      • 10.3.17.1. Company overview
      • 10.3.17.2. Financial performance
      • 10.3.17.3. Usage benchmarking
      • 10.3.17.4. Strategic initiatives
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦